Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer Study
Phase: 1b
Status: Ongoing
About
Phase 1b of a study of DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
Details
A Phase 1b, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-ADC, in Combination with Pembrolizumab, an Anti-PD-1 Antibody, in Subjects with Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer (NSCLC)
Sponsor: Daiichi Sankyo, Inc
NCT04042701
